Cheaper Alternative to Repatha: Cost vs PCSK9 Options
Repatha costs about $6,168 a year (WAC). Compare Praluent, inclisiran, statins and ezetimibe prices to find a cheaper LDL-lowering option.
Evolocumab
94 source-based articles maintained by the HealthRX.com Editorial Team.
94articles
7topic areas covered
May 27, 2026latest review
Evolocumab library
Showing 94 of 94 clinical reviews.
Does Aetna (CVS Health) Cover Repatha (Evolocumab)?
A clinical guide to Aetna's Repatha coverage policy: prior authorization criteria, step therapy requirements, formulary tier, appeal process, and cost-assistance options for evolocumab.
Does Anthem (Elevance Health) Cover Repatha (Evolocumab)?
A complete guide to Anthem (Elevance Health) Repatha coverage: prior authorization criteria, step therapy requirements, formulary tier, appeal strategy, and cost-savings options for evolocumab.
Does Blue Cross Blue Shield (Federated) Cover Repatha (Evolocumab)?
A clinical and practical guide to Blue Cross Blue Shield Federated coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, appeal strategies, and cost options for 2024.
Does Humana Cover Repatha (Evolocumab)? Coverage, Prior Auth, and Appeals
A complete guide to Humana coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and manufacturer savings options.
Does Kaiser Permanente Cover Repatha (Evolocumab)?
A clinical guide to Kaiser Permanente's Repatha (evolocumab) coverage: formulary tier, prior authorization criteria, step therapy requirements, appeals process, and patient savings options.
Does Medicare Advantage Cover Repatha (Evolocumab)?
Medicare Advantage plans cover Repatha (evolocumab) through Part D for familial hypercholesterolemia and established cardiovascular disease, but prior authorization and step therapy are near-universal hurdles. Here is what determines approval.
Does TRICARE Cover Repatha (Evolocumab)? Coverage, Prior Auth, and Appeals Explained
A complete guide to TRICARE coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, formulary tier, and how to appeal a denial. prepared by the HealthRX.com Editorial Team.
Evolocumab Pharmacogenomics: How Genetic Variability Shapes Repatha Response
A clinical deep-dive into how PCSK9, LDLR, and APOE gene variants influence evolocumab (Repatha) efficacy, safety, and dosing decisions.
How to Get Repatha (Evolocumab) in Arizona
A complete guide to obtaining a Repatha prescription in Arizona, including telehealth options, prior authorization requirements, lab work, and pharmacy access for evolocumab.
How to Get Repatha (Evolocumab) in California
A complete guide to obtaining a Repatha prescription in California, covering telehealth access, prior authorization, labs, pharmacy options, and the clinical evidence behind PCSK9 inhibitor therapy.
How to Get Repatha (Evolocumab) in Florida
A step-by-step clinical guide to obtaining a Repatha (evolocumab) prescription in Florida, including telehealth options, prior authorization requirements, lab work, and pharmacy logistics.
How to Get Repatha (Evolocumab) in Hawaii
A complete guide to obtaining a Repatha (evolocumab) prescription in Hawaii, including telehealth options, prior authorization requirements, pharmacy access, and what labs you need before your first dose.
How to Get Repatha (Evolocumab) in Indiana
A step-by-step guide to getting a Repatha prescription in Indiana, including telehealth options, prior authorization requirements, pharmacy access, and cost-saving strategies for evolocumab.
How to Get Repatha (Evolocumab) in Kansas
A step-by-step guide to getting a Repatha (evolocumab) prescription in Kansas, including telehealth options, prior authorization, lab requirements, pharmacy fulfillment, and cost-assistance programs, with a checklist for separating stable facts from ones that change.
How to Get Repatha (Evolocumab) in Maine
A complete guide to getting a Repatha (evolocumab) prescription in Maine, covering telehealth options, prior authorization, lab requirements, pharmacy delivery, and cost assistance.
How to Get Repatha (Evolocumab) in New Hampshire
A complete guide to getting a Repatha (evolocumab) prescription in New Hampshire, including telehealth options, prior authorization requirements, lab work, pharmacy access, and cost assistance programs.
How to Get Repatha (Evolocumab) in New Mexico
A complete guide to obtaining a Repatha (evolocumab) prescription in New Mexico, including telehealth options, prior authorization requirements, lab work, pharmacy logistics, and cost-assistance programs.
How to Get Repatha (Evolocumab) in New York
A clinical guide to obtaining a Repatha (evolocumab) prescription in New York, covering telehealth access, required labs, prior authorization, and pharmacy options, with a clear separation of stable clinical facts from insurer- and date-specific details that require independent verification.
How to Get Repatha (Evolocumab) in Ohio
A step-by-step guide to obtaining a Repatha (evolocumab) prescription in Ohio, including telehealth options, prior authorization requirements, pharmacy access, and lab work needed before your first dose.
How to Get Repatha (Evolocumab) in Oklahoma
A step-by-step clinical guide to getting a Repatha (evolocumab) prescription in Oklahoma, including telehealth options, prior authorization, labs, and pharmacy access.
How to Get Repatha (Evolocumab) in Oregon
A complete guide to obtaining a Repatha (evolocumab) prescription in Oregon, including telehealth options, prior authorization requirements, lab work, pharmacy logistics, and cost-assistance programs.
How to Get Repatha (Evolocumab) in Virginia
A step-by-step clinical guide to obtaining a Repatha (evolocumab) prescription in Virginia, including telehealth options, prior authorization, labs, and pharmacy access.
How to Get Repatha (Evolocumab) in Washington State
A complete guide to obtaining a Repatha prescription in Washington, including telehealth options, prior authorization steps, pharmacy access, and the clinical evidence behind evolocumab for high LDL and ASCVD.
How to Get Repatha in Alaska: Prescriptions, Telehealth, and Pharmacy Access
A complete guide to getting evolocumab (Repatha) in Alaska, covering telehealth prescribers, prior authorization, labs, pharmacy options, and shipping timelines.
How to Get Repatha in New Jersey: Prescriptions, Telehealth, and Insurance
A complete guide to getting evolocumab (Repatha) in New Jersey, covering telehealth prescribing, prior authorization, labs, pharmacy options, and NJ Medicaid coverage.
How to Get Repatha in South Carolina: Prescriptions, Telehealth, and Prior Authorization
A complete guide to accessing evolocumab (Repatha) in South Carolina, covering telehealth prescribing, required labs, prior authorization, pharmacy options, and cost assistance programs.
How to Safely Stop Repatha (Evolocumab): A Discontinuation Protocol
Repatha side effects are mild for most: injection-site reactions in 5.7% vs 4.2% on placebo, plus nasopharyngitis and myalgia. Stopping needs no taper.
Leqvio Office Injection vs Repatha Self-Injection at Home
Leqvio is given by a provider twice yearly in-office; Repatha is self-injected every 2 weeks or monthly. Compares devices, technique, and dosing schedules.
Repatha (Evolocumab) Adolescent Dosing: Complete Guide for Ages 12 to 17
Evidence-based dosing guide for evolocumab (Repatha) in adolescents aged 12, 17 with heterozygous or homozygous familial hypercholesterolemia. Covers FDA-approved doses, injection schedules, monitoring, and trial data.
Repatha (Evolocumab) Adult Dosing for Ages 30 to 49: Schedule, Administration, and What to Expect
A guide to Repatha (evolocumab) dosing for adults aged 30 to 49, covering FDA-approved schedules, injection technique, missed-dose handling, and what remains individualized versus standardized.
Repatha (Evolocumab) Complete Drug-Drug Interaction Profile
A clinician-grade review of evolocumab (Repatha) drug-drug interactions, covering statins, ezetimibe, warfarin, immunosuppressants, and more, with PubMed-cited evidence.
Repatha (Evolocumab) Dosing for Adults 65 and Older
Evidence-based guide to evolocumab (Repatha) dosing in geriatric patients aged 65+, covering pharmacokinetics, renal considerations, FOURIER trial data, and practical injection guidance.
Repatha (Evolocumab) Dosing for Older Adults (50 to 64): What Clinicians and Patients Should Know
Evidence-based guide to evolocumab (Repatha) dosing in adults aged 50 to 64, including standard protocols, age-specific considerations, monitoring, and perimenopause/andropause overlap.
Repatha (Evolocumab) Dosing for Young Adults (18 to 29): Schedule, Evidence, and Practical Tips
Evidence-based guide to Repatha (evolocumab) dosing in young adults aged 18 to 29, covering FDA-approved schedules, clinical trial data, fertility considerations, and injection technique.
Repatha (Evolocumab) Dosing in Hepatic Impairment
Evidence-based guide to evolocumab (Repatha) dosing in patients with hepatic impairment, including pharmacokinetic data, FDA labeling, clinical trial evidence, and practical monitoring recommendations.
Repatha (Evolocumab) Dosing in Renal Impairment
Evidence-based guide to evolocumab (Repatha) dosing in patients with chronic kidney disease. Covers pharmacokinetics, clinical trial data, FDA labeling, and practical prescribing considerations for renal impairment.
Repatha (Evolocumab) Food & Supplement Interactions: What to Know Before You Inject
A guide to evolocumab (Repatha) food and supplement interactions, including grapefruit, fish oil, red yeast rice, CoQ10, and more.
Repatha (Evolocumab) Future Formulations and Pipeline: What Comes Next for PCSK9 Therapy
A clinical review of evolocumab's mechanism of action, the FOURIER trial evidence base, and the next-generation PCSK9 pipeline including oral inhibitors, siRNA, and gene-editing approaches.
Repatha (Evolocumab) in Pregnancy and Lactation: Safety Evidence and Clinical Guidance
What clinicians and patients need to know about evolocumab (Repatha) use during pregnancy and breastfeeding, including animal data, placental transfer risks, and alternative lipid-lowering strategies.
Repatha (Evolocumab) in Special Populations: Transplant, HIV, CKD, and Beyond
Evidence-based guide to using evolocumab (Repatha) in transplant recipients, people living with HIV, chronic kidney disease, elderly patients, and other special populations where standard lipid therapy falls short.
Repatha (Evolocumab) Manufacturing, Supply & Shortage History
A clinical deep-dive into Repatha's manufacturing process, supply chain structure, and documented shortage events, with FDA-sourced evidence and clearly flagged areas needing verification.
Repatha (Evolocumab) Mechanism of Action: The Full PCSK9 Pathway Explained
A physician-level explanation of how evolocumab (Repatha) works, from PCSK9 binding to LDL receptor recycling to cardiovascular risk reduction, with trial data from FOURIER and beyond.
Repatha (Evolocumab) Missed-Dose Protocol: What to Do and When
Evidence-based missed-dose protocol for Repatha (evolocumab), including timing rules for biweekly and monthly schedules, pharmacokinetic rationale, and clinical guidance from the FDA label.
Repatha (Evolocumab) Monitoring for Adults 65 and Older
Evidence-based monitoring guide for evolocumab (Repatha) in geriatric patients 65+. Covers lipid panels, liver and renal function, cognitive screening, injection-site checks, and deprescribing criteria.
Repatha (Evolocumab) Monitoring for Adults Age 30 to 49
Evidence-based monitoring schedule for evolocumab (Repatha) in adults aged 30 to 49, including lipid panels, liver function, injection-site checks, and PCSK9 inhibitor safety labs.
Repatha (Evolocumab) Monitoring for Older Adults (50 to 64): Lab Schedule, Safety Checks, and Clinical Benchmarks
Evidence-based monitoring guide for evolocumab (Repatha) in adults aged 50 to 64, covering lipid panels, hepatic function, neurocognitive screening, injection-site tracking, and cardiovascular risk reassessment.
Repatha (Evolocumab) Monitoring for Young Adults (18 to 29): Labs, Timelines, and What to Watch
Complete monitoring guide for young adults aged 18 to 29 taking Repatha (evolocumab), including lab schedules, lipid targets, safety markers, and fertility considerations.
Repatha (Evolocumab) Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination
A clinician-grade review of evolocumab (Repatha) pharmacokinetics covering ADME, target-mediated disposition, half-life, dosing intervals, and special-population considerations with PubMed-cited evidence.
Repatha (Evolocumab) Real-World Evidence: What Registries and RWE Studies Actually Show
A review of what is and is not established about evolocumab (Repatha) outside of clinical trials, including adherence patterns, LDL-C lowering in practice, and open questions in cardiovascular outcome data.
Repatha (Evolocumab) Regulatory Status: US, EU, Canada, and UK Approvals
A clinical review of evolocumab (Repatha) regulatory approvals across the US, EU, Canada, and UK, including approved indications, dosing, PCSK9 mechanism, and where label approval diverges from actual insurance or NHS access.
Repatha (Evolocumab) Safety for Adults Ages 30 to 49: What the Evidence Actually Shows
An evidence-based guide to evolocumab (Repatha) safety in adults aged 30, 49, covering trial data, injection-site reactions, neurocognitive signals, muscle effects, and clinical monitoring.
Repatha (Evolocumab) Safety in Adults 65 and Older
Evidence-based review of evolocumab (Repatha) safety in geriatric patients, including subgroup findings from cardiovascular outcomes trials, neurocognitive data, fall risk, renal considerations, and deprescribing guidance.
Repatha (Evolocumab) Safety in Children Under 12: What Parents and Clinicians Need to Know
A comprehensive clinical review of evolocumab (Repatha) safety in pediatric patients under age 12, covering FDA labeling, dosing, monitoring, trial evidence, and guideline recommendations.
Repatha (Evolocumab) Safety in Older Adults (50-64): Clinical Evidence and Monitoring
A clinical review of evolocumab (Repatha) safety data in the 50-64 age group, covering FOURIER trial evidence, side effects, neurocognitive outcomes, polypharmacy considerations, and monitoring guidance.
Repatha (Evolocumab) Safety in Young Adults Ages 18 to 29
A clinical review of evolocumab (Repatha) safety for young adults aged 18, 29, covering injection-site reactions, neurocognitive findings, fertility considerations, long-term data, and how PCSK9 inhibition fits into early-onset familial hypercholesterolemia management.
Repatha (Evolocumab) Safety Signals and FDA Actions: What the Evidence Shows
A physician-level review of evolocumab (Repatha) safety signals, FDA regulatory actions, post-marketing surveillance data, and clinical trial safety outcomes from FOURIER and EBBINGHAUS.
Repatha (Evolocumab): History and Development
A complete timeline of evolocumab from the 2003 discovery of PCSK9 through FDA approval, the FOURIER outcomes trial, and label expansions. Mechanism, clinical evidence, and pricing milestones.
Repatha Cost in Alaska 2026: Prices, Insurance, Medicaid, and Compounded Alternatives
Everything Alaska residents need to know about evolocumab (Repatha) pricing in 2026, including Medicaid coverage status, compounded evolocumab legality, insurance prior authorization, and legitimate savings strategies.
Repatha Cost in Arizona 2026: Price, Insurance, Medicaid, and Compounding Options
Complete guide to evolocumab (Repatha) cost in Arizona for 2026. Covers list price, insurance coverage, Arizona Medicaid status, compounded evolocumab legality, the Amgen savings card, and telehealth prescribing.
Showing the first 60 matches. Use search or filters to narrow the library.